No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes
- PMID: 17327427
- DOI: 10.2337/db06-1248
No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes
Abstract
Regulatory T-cells (Tregs) play a critical role in maintaining dominant peripheral tolerance. Previous characterizations of Tregs in type 1 diabetes have used antibodies against CD4 and alpha-chain of the interleukin-2 receptor complex (CD25). This report extends those investigations by the addition of a more lineage-specific marker for Tregs, transcription factor forkhead box P3 (FOXP3), in subjects with type 1 diabetes, their first-degree relatives, and healthy control subjects. With inclusion of this marker, two predominant populations of CD4(+)CD25(+) T-cells were identified: CD4(+)CD25(+)FOXP3(+) as well as CD4(+)FOXP3(-) T-cells expressing low levels of CD25 (CD4(+)CD25(LOW)FOXP3(-)). In all study groups, the frequency of CD4(+)CD25(+)FOXP3(+) cells was age independent, whereas CD4(+)CD25(LOW)FOXP3(-) cell frequencies strongly associated with age. In terms of additional markers for delineating cells of Treg lineage, FOXP3(+) cells were CD127(-) to CD127(LOW) whereas CD25(+) cells were less restricted in their expression of this marker, with CD127 expressed across a continuum of levels. Importantly, no differences were observed in the frequency of CD4(+)CD25(+)FOXP3(+) T-cells in individuals with or at varying degrees of risk for type 1 diabetes. These investigations suggest that altered peripheral blood frequencies of Tregs, as defined by the expression of FOXP3, are not specifically associated with type 1 diabetes and continue to highlight age as an important variable in analysis of immune regulation.
Similar articles
-
CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression.Clin Immunol. 2009 Apr;131(1):109-18. doi: 10.1016/j.clim.2008.11.010. Epub 2009 Jan 18. Clin Immunol. 2009. PMID: 19153062
-
Correlation between the degree of immune activation, production of IL-2 and FOXP3 expression in CD4+CD25+ T regulatory cells in HIV-1 infected persons under HAART.Int Immunopharmacol. 2009 Jul;9(7-8):831-6. doi: 10.1016/j.intimp.2009.03.009. Epub 2009 Mar 18. Int Immunopharmacol. 2009. PMID: 19303058
-
Frequency of Foxp3+CD4CD25+ T cells is associated with the phenotypes of allergic asthma.Respirology. 2009 Mar;14(2):187-94. doi: 10.1111/j.1440-1843.2008.01472.x. Epub 2009 Jan 23. Respirology. 2009. PMID: 19192224
-
Cell-surface IL-7 receptor expression facilitates the purification of FOXP3(+) regulatory T cells.Trends Immunol. 2006 Dec;27(12):541-4. doi: 10.1016/j.it.2006.10.002. Epub 2006 Oct 12. Trends Immunol. 2006. PMID: 17045841 Review.
-
The regulation of Foxp3 expression in regulatory CD4(+)CD25(+)T cells: multiple pathways on the road.J Cell Physiol. 2007 Jun;211(3):590-7. doi: 10.1002/jcp.21001. J Cell Physiol. 2007. PMID: 17311282 Review.
Cited by
-
Combined unsupervised and semi-automated supervised analysis of flow cytometry data reveals cellular fingerprint associated with newly diagnosed pediatric type 1 diabetes.Front Immunol. 2022 Oct 27;13:1026416. doi: 10.3389/fimmu.2022.1026416. eCollection 2022. Front Immunol. 2022. PMID: 36389771 Free PMC article.
-
Mechanisms and therapeutic strategies of immune checkpoint molecules and regulators in type 1 diabetes.Front Endocrinol (Lausanne). 2023 Jan 10;13:1090842. doi: 10.3389/fendo.2022.1090842. eCollection 2022. Front Endocrinol (Lausanne). 2023. PMID: 36704045 Free PMC article. Review.
-
Increased resistance to CD4+CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes.Clin Exp Immunol. 2008 Dec;154(3):353-9. doi: 10.1111/j.1365-2249.2008.03810.x. Clin Exp Immunol. 2008. PMID: 19037920 Free PMC article.
-
Regulatory T cells and their role in rheumatic diseases: a potential target for novel therapeutic development.Pediatr Rheumatol Online J. 2008 Dec 1;6:20. doi: 10.1186/1546-0096-6-20. Pediatr Rheumatol Online J. 2008. PMID: 19046457 Free PMC article.
-
Persistent suppression of type 1 diabetes by a multicomponent vaccine containing a cholera toxin B subunit-autoantigen fusion protein and complete Freund's adjuvant.Clin Dev Immunol. 2013;2013:578786. doi: 10.1155/2013/578786. Epub 2013 Nov 11. Clin Dev Immunol. 2013. PMID: 24319466 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials